Biogen Inc. · NASDAQ (us_market)
Healthcare · Drug Manufacturers - General · United States
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2024-12-02$164.23 RISE2025-04-10$113.38 PEAK2025-06-10$135.49 190d | -31.0% 129d | 2025-02-14 $137.33 | 2025-06-10 $135.49 | 67Deep Value | 70Deep Value | +19.5% 61d | -1.3% Held 116d |
DROP2024-01-02$267.71 RISE2024-04-18$190.52 PEAK2024-07-11$236.80 191d | -28.8% 107d | Missed | Missed | — | — | +24.3% 84d | Missed |
DROP2023-07-10$281.58 RISE2023-11-13$222.59 PEAK2024-01-02$267.71 176d | -20.9% 126d | Missed | Missed | — | — | +20.3% 50d | Missed |
DROP2022-11-22$306.72 RISE2023-03-10$256.56 PEAK2023-05-05$318.06 164d | -16.4% 108d | Missed | Missed | — | — | +24.0% 56d | Missed |
DROP2022-02-09$226.81 RISE2022-06-16$191.53 PEAK2022-08-15$222.38 187d | -15.6% 127d | Missed | Missed | — | — | +16.1% 60d | Missed |
DROP2021-12-29$258.31 RISE2022-05-09$187.54 PEAK2022-07-19$220.26 202d | -27.4% 131d | Missed | Missed | — | — | +17.4% 71d | Missed |
DROP2021-11-04$280.41 RISE2022-03-14$193.77 PEAK2022-04-19$223.02 166d | -30.9% 130d | Missed | Missed | — | — | +15.1% 36d | Missed |
DROP2021-08-17$349.79 RISE2021-12-03$223.92 PEAK2021-12-29$258.31 134d | -36.0% 108d | Missed | Missed | — | — | +15.4% 26d | Missed |
DROP2020-11-04$355.63 RISE2021-03-16$259.92 PEAK2021-06-10$414.71 218d | -26.9% 132d | Missed | Missed | — | — | +59.6% 86d | Missed |
DROP2020-11-04$355.63 RISE2020-11-09$236.26 PEAK2021-01-29$282.61 86d | -33.6% 5d | Missed | Missed | — | — | +19.6% 81d | Missed |
DROP2020-05-11$328.01 RISE2020-09-10$266.51 PEAK2020-11-04$355.63 177d | -18.7% 122d | Missed | Missed | — | — | +33.4% 55d | Missed |
DROP2020-04-17$342.55 RISE2020-06-26$258.66 PEAK2020-08-07$305.71 112d | -24.5% 70d | Missed | Missed | — | — | +18.2% 42d | Missed |
DROP2020-02-19$341.04 RISE2020-03-12$268.88 PEAK2020-04-17$342.55 58d | -21.2% 22d | Missed | Missed | — | — | +27.4% 36d | Missed |
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ionis Pharmaceuticals (NASDAQ:IONS) highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets’ Global Healthcare Conference, with Chief Development Officer Holly Kordasiewicz saying the company is moving from recent launch
Ionis Pharmaceuticals (NASDAQ:IONS) highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets’ Global Healthcare Conference, with Chief Development Officer Holly Kordasiewicz saying the company is moving from recent launch
Stocks were up sharply to end the week as NVIDIA’s forward guidance showed tangible demand to support AI infrastructure and overshadowed mixed retail reports
Stocks were up sharply to end the week as NVIDIA’s forward guidance showed tangible demand to support AI infrastructure and overshadowed mixed retail reports
Biogen and Denali Therapeutics halted development of experimental Parkinson's therapy BIIB122 after the Phase 2b LUMA study failed to meet its endpoints. Legal investigations have been launched into Biogen following missed endpoints in the Phase 2 CELIA study for Alzheimer's therapy diranersen. These developments affect Biogen's pipeline in neurodegenerative diseases and add legal and regulatory scrutiny around its R&D disclosures. For investors following NasdaqGS:BIIB, the halt of BIIB122...
Biogen and Denali Therapeutics halted development of experimental Parkinson's therapy BIIB122 after the Phase 2b LUMA study failed to meet its endpoints. Legal investigations have been launched into Biogen following missed endpoints in the Phase 2 CELIA study for Alzheimer's therapy diranersen. These developments affect Biogen's pipeline in neurodegenerative diseases and add legal and regulatory scrutiny around its R&D disclosures. For investors following NasdaqGS:BIIB, the halt of BIIB122...
DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.
DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.
Biogen’s Alzheimer’s drug candidate showed promising tau-targeting results despite missing a primary endpoint, reinforcing long-term optimism for BIIB stock
Biogen’s Alzheimer’s drug candidate showed promising tau-targeting results despite missing a primary endpoint, reinforcing long-term optimism for BIIB stock
High-level results have led the companies to scrap a mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson’s patients.
High-level results have led the companies to scrap the mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson’s patients.
The study did not show that the drug slowed the worsening of motor and daily-living symptoms compared with placebo, the company said.
The study did not show that the drug slowed the worsening of motor and daily-living symptoms compared with placebo, the company said.
The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue development of BIIB122 in idiopathic Parkinson’s diseaseDenali continues to independently conduct the Phase 2a BEACON study in carriers of a pathogenic LRRK2 variant CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc
The Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue development of
Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies for neurologic diseases, said it has appointed biopharmaceutical veteran Michael Bonney as chair of its board of directors. Bonney brings more than three decades of industry experience, including...
Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies for neurologic diseases, said it has appointed biopharmaceutical veteran Michael Bonney as chair of its board of directors. Bonney brings more than three decades of industry experience, including...
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Michael "Mike" W. Bonney, a highly experienced biopharmaceutical executive and board leader, as Chair of its Board of Directors, effective May 16, 2026. Simona Skerjanec, M.Pharm, MBA, will transition from Interim Chairperson to continue serving as a member of the Board.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BIIB | +4.78% | +4.23% | +11.37% | +51.01% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +1.81% | +9.94% | +14.81% | +38.32% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 12.81M | $2.35B | 0.12% | Added+35.9% | 2026-03-31 |
| StateStreet | passive | 7.17M | $1.31B | 0.05% | Unchanged | 2026-03-31 |
| Wellington | fundamental | 2.96M | $542.96M | 0.10% | Trimmed-16.6% | 2026-03-31 |
| Citadel | multi-strat | 809.6K | $148.43M | 0.19% | Trimmed-71.2% | 2026-03-31 |
| RenTech | quant | 203.4K | $37.29M | 0.06% | Trimmed-49.0% | 2026-03-31 |
| TwoSigma | quant | 9.4K | $1.73M | 0.00% | Trimmed-96.2% | 2026-03-31 |
| TRowePrice | fundamental | 672.4K | $123.28K | 0.01% | Trimmed-15.1% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-05 | Keeney Adam | Head of Corporate Development | M Option exercise(deriv) | 939 | — | +$0 |
| 2026-05-05 | Keeney Adam | Head of Corporate Development | F Tax withholding | 455 | $187.06 | −$85.1K |
| 2026-05-05 | Keeney Adam | Head of Corporate Development | M Option exercise | 939 | — | +$0 |
| 2026-04-03 | Godbout Sean | Chief Accounting Officer | M Option exercise(deriv) | 181 | — | +$0 |
| 2026-04-03 | Godbout Sean | Chief Accounting Officer | F Tax withholding | 54 | $183.78 | −$9.9K |
| 2026-04-03 | Godbout Sean | Chief Accounting Officer | M Option exercise | 181 | — | +$0 |
| 2026-02-17 | ALEXANDER SUSAN H | EVP Chief Legal Officer | A Grant / award(deriv) | 8,450 | — | +$0 |
| 2026-02-17 | Godbout Sean | Chief Accounting Officer | A Grant / award(deriv) | 1,800 | — | +$0 |
| 2026-02-17 | Gregory Ginger | EVP, Human Resources | A Grant / award(deriv) | 8,025 | — | +$0 |
| 2026-02-17 | Grogan Jane | Head of Research | A Grant / award(deriv) | 8,450 | — | +$0 |
| 2026-02-17 | Izzar Rachid | Head of Global Product Strat. | A Grant / award(deriv) | 7,390 | — | +$0 |
| 2026-02-17 | Keeney Adam | Head of Corporate Development | A Grant / award(deriv) | 8,025 | — | +$0 |
| 2026-02-17 | Kramer Robin | Chief Financial Officer | A Grant / award(deriv) | 8,450 | — | +$0 |
| 2026-02-17 | Murphy Nicole | Head of Pharm Ops and Tech | A Grant / award(deriv) | 10,560 | — | +$0 |
| 2026-02-17 | Murphy Nicole | Head of Pharm Ops and Tech | P Open-market purchase | 3 | $195.03 | +$585 |
| 2026-02-17 | Singhal Priya | Head of Development | A Grant / award(deriv) | 10,560 | — | +$0 |
| 2026-02-17 | Viehbacher Christopher | President and CEO | A Grant / award(deriv) | 38,015 | — | +$0 |
| 2026-02-10 | ALEXANDER SUSAN H | EVP Chief Legal Officer | M Option exercise(deriv) | 4,916 | — | +$0 |
| 2026-02-10 | ALEXANDER SUSAN H | EVP Chief Legal Officer | M Option exercise(deriv) | 1,940 | — | +$0 |
| 2026-02-10 | ALEXANDER SUSAN H | EVP Chief Legal Officer | M Option exercise(deriv) | 2,190 | — | +$0 |
| 2026-02-10 | ALEXANDER SUSAN H | EVP Chief Legal Officer | F Tax withholding | 1,514 | $201.18 | −$304.6K |
| 2026-02-10 | ALEXANDER SUSAN H | EVP Chief Legal Officer | M Option exercise | 4,916 | — | +$0 |
| 2026-02-10 | ALEXANDER SUSAN H | EVP Chief Legal Officer | F Tax withholding | 931 | $201.18 | −$187.3K |
| 2026-02-10 | ALEXANDER SUSAN H | EVP Chief Legal Officer | M Option exercise | 1,940 | — | +$0 |
| 2026-02-10 | ALEXANDER SUSAN H | EVP Chief Legal Officer | F Tax withholding | 1,059 | $201.18 | −$213.0K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-30upcoming | 1.94 | — | — |
| 2026-04-29 | 2.89 | 3.57 | +23.61% |
| 2026-02-06 | 1.62 | 1.99 | +23.18% |
| 2025-10-30 | 3.88 | 4.81 | +23.88% |
| 2025-07-31 | 3.88 | 5.47 | +40.97% |
| 2025-05-01 | 2.95 | 3.02 | +2.43% |
| 2025-02-12 | 3.36 | 3.44 | +2.26% |
| 2024-10-30 | 3.79 | 4.08 | +7.79% |
| 2024-08-01 | 4.03 | 5.28 | +31.03% |
| 2024-04-24 | 3.46 | 3.67 | +6.00% |
| 2024-02-13 | 3.18 | 2.95 | -7.21% |
| 2023-11-08 | 3.98 | 4.36 | +9.42% |
| 2023-07-25 | 3.76 | 4.02 | +6.90% |
| 2023-04-25 | 3.28 | 3.40 | +3.53% |
| 2023-02-15 | 3.48 | 4.05 | +16.24% |
| 2022-10-25 | 4.13 | 4.77 | +15.50% |